Amarin yesterday received a positive 16-0 FDA panel vote for Vascepa label expansion approval which is most important, although predictably there was a "mixed" discussion about labeling, Jefferies analyst Michael Yee tells investors in a research note. The analyst keeps a Buy rating on the shares with a $30 price target. He says his thesis and valuation are not based on specific "details" of a label as he thinks doctors will use Vascepa widely across patients regardless. The stock will bounce on any dips because the label details don't matter in the big picture, contends Yee. Amarin in premarket trading is up 6%, or $1.22, to $22.71.